Course Overview
The available novel diabetes therapies and their impact on cardiovascular and cardiometabolic risk reduction are discussed by guests Chris Memering, MSN, RN, CDCES, BC-ADM, FADCES, and Sun Kim, MD. A particular emphasis on GLP-1 receptor agonists and the patients for whom they are guideline-recommended, as well as ongoing research, are also covered.
Earn 0.6 CE contact hours, including 0.6 pharmacology, from listening by listening to the podcast episode and completing the course components.
Member Cost: $0Non-member Cost: $0
Credits: 0.6 CE contact hours, 0.6 CE pharmacology hours
Learning Objectives
1. Discuss available novel diabetes therapies and their impact on cardiovascular and cardiometabolic risk reduction
2. Explore the mechanism of action and study results of the GLP1 medication class
CE certificate available upon successful completion of the post-test and program evaluation.
Faculty
- Chris Memering, MSN, RN, CDCES, BC-ADM, FADCES
- Sun Kim, MD
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.